11.22.21
Novel ingredient developer NXT USA has received a U.S. composition patent for its flagship ingredient TamaFlex, titled “Synergistic Composition for Osteoarthritis.” The ingredient is the only product on the market today which combines tamarind seed and turmeric rhizome extracts, according to the company.
The patent relates to a synergistic composition featuring a combination of therapeutically-efficacious amounts of Tamarindus indica seed extract and Curcuma longa rhizome extract for applications including inflammation, joint function, and collagen breakdown. The patent protects Tamaflex in a variety of preparations and dosages.
TamaFlex is backed by human clinical trials which substantiate the use of the aforementioned claims, and has also been evidenced to support connective tissue and joint integrity. Trials to date rely on both self-reported data as well as performance measurements in joint function tests.
“This is a validating event for the researchers that created TamaFlex, for NXT USA, and also for TamaFlex consumers. It is a game-changer that this novel composition is recognized for a U.S. patent, because it supports the discovery, development, and clinical substantiation that backs this exciting new ingredient,” Eric Anderson, managing director of NXT USA, said. “TamaFlex is clinically-validated in both healthy participants and participants with mild joint discomfort to provide benefits in just five days. In comparison, most joint products rely on data from folks with existing health conditions and need extended periods of time to provide efficacy.”
According to NXT USA, Tamaflex targets two enzymatic pathways linked to joint inflammation – the COX-2 and 5-LOX pathways. Most joint health products available on today’s market address only one of the two pathways.
The patent relates to a synergistic composition featuring a combination of therapeutically-efficacious amounts of Tamarindus indica seed extract and Curcuma longa rhizome extract for applications including inflammation, joint function, and collagen breakdown. The patent protects Tamaflex in a variety of preparations and dosages.
TamaFlex is backed by human clinical trials which substantiate the use of the aforementioned claims, and has also been evidenced to support connective tissue and joint integrity. Trials to date rely on both self-reported data as well as performance measurements in joint function tests.
“This is a validating event for the researchers that created TamaFlex, for NXT USA, and also for TamaFlex consumers. It is a game-changer that this novel composition is recognized for a U.S. patent, because it supports the discovery, development, and clinical substantiation that backs this exciting new ingredient,” Eric Anderson, managing director of NXT USA, said. “TamaFlex is clinically-validated in both healthy participants and participants with mild joint discomfort to provide benefits in just five days. In comparison, most joint products rely on data from folks with existing health conditions and need extended periods of time to provide efficacy.”
According to NXT USA, Tamaflex targets two enzymatic pathways linked to joint inflammation – the COX-2 and 5-LOX pathways. Most joint health products available on today’s market address only one of the two pathways.
